HTG Molecular Diagnostics, Inc. Deferred Tax Assets, Net of Valuation Allowance
HTG Molecular Diagnostics, Inc. had Deferred Tax Assets, Net of Valuation Allowance of $263.07 thousand as of 2022-12-31, per its 10-K filed 2023-03-30.
Discontinued › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance
us-gaap:DeferredTaxAssetsNet · last filed 2023-03-30
- 2022-12-31: Deferred Tax Assets, Net of Valuation Allowance $263.07K.
- 2021-12-31: Deferred Tax Assets, Net of Valuation Allowance $361.82K.
- 2020-12-31: Deferred Tax Assets, Net of Valuation Allowance $282.71K.
- 2019-12-31: Deferred Tax Assets, Net of Valuation Allowance $417.43K.
| Period end | Deferred Tax Assets, Net of Valuation Allowance |
|---|---|
| 2022-12-31 | $263.07K 10-K · filed 2023-03-30 |
| 2021-12-31 | $361.82K 10-K · filed 2023-03-30 |
| 2020-12-31 | $282.71K 10-K · filed 2022-03-29 |
| 2019-12-31 | $417.43K 10-K · filed 2021-03-25 |